ITM firing on all cylinders as key milestones keep coming
The days of flying under the radar are over for Isotope Technologies Munich (ITM), a privately-held German radiopharmaceutical company.
ITM has been one of the foundational pillars of radiopharmaceuticals in the past 20 years or so, as a manufacturer and supplier of medical radioisotopes that is also developing its own broad precision oncology pipeline.
The company has not always had the profile of the pharma companies that it provides radioisotopes for, such as Novartis (NOVN: VX). The Munich firm is a supplier for the Swiss pharma giant’s approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which is seen as an important frontrunner in the field.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze